The implications of high prices for cancer drugs on health care costs and patients' financial burdens are a growing concern. Patients with metastatic castrate-resistant prostate cancer (mCRPC) are ...
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA. Keynote 057: Phase II trial of Pembrolizumab ...
Targeted cancer therapies are an expanding field of effective therapeutic approaches. While previous chemotherapy agents indiscriminately killed rapidly proliferating cells, newer “precision medicine” ...
An expert on prostate cancer gives a brief overview of castrate-resistant prostate cancer. This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD, MPH, of ...
According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime. In addition, about 1 in 44 men will die from the disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results